En­do inks $465M bank­rupt­cy deal set­tling crim­i­nal and civ­il opi­oid cas­es

En­do agreed to pay up to $464.9 mil­lion to re­solve claims around the mar­ket­ing of its for­mer opi­oid pain med­ica­tion Opana ER.

The com­pa­ny this week an­nounced a se­ries of set­tle­ments, in­clud­ing a bank­rupt­cy agree­ment that calls for 10 an­nu­al pay­ments to the fed­er­al gov­ern­ment to­tal­ing $364.9 mil­lion. The deal al­so in­cludes an ad­di­tion­al pay­ment of up to $100 mil­lion, de­pend­ing on the “busi­ness per­for­mance of the new com­pa­ny.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.